- Home
- MASI vs LEGN Comparison
MASI vs LEGN Comparison
Compare MASI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASI
- LEGN
- Stock Information
- Founded
- MASI 1989
- LEGN 2014
- Country
- MASI United States
- LEGN United States
- Employees
- MASI N/A
- LEGN N/A
- Industry
- MASI Medical/Dental Instruments
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- MASI Health Care
- LEGN Health Care
- Exchange
- MASI Nasdaq
- LEGN Nasdaq
- Market Cap
- MASI 8.1B
- LEGN 6.7B
- IPO Year
- MASI 2007
- LEGN 2020
- Fundamental
- Price
- MASI $141.66
- LEGN $34.45
- Analyst Decision
- MASI Buy
- LEGN Strong Buy
- Analyst Count
- MASI 6
- LEGN 12
- Target Price
- MASI $194.60
- LEGN $73.36
- AVG Volume (30 Days)
- MASI 608.9K
- LEGN 1.1M
- Earning Date
- MASI 11-04-2025
- LEGN 11-11-2025
- Dividend Yield
- MASI N/A
- LEGN N/A
- EPS Growth
- MASI N/A
- LEGN N/A
- EPS
- MASI N/A
- LEGN N/A
- Revenue
- MASI $2,153,800,000.00
- LEGN $796,838,000.00
- Revenue This Year
- MASI N/A
- LEGN $70.75
- Revenue Next Year
- MASI $7.80
- LEGN $52.47
- P/E Ratio
- MASI N/A
- LEGN N/A
- Revenue Growth
- MASI 25.86
- LEGN 74.75
- 52 Week Low
- MASI $111.03
- LEGN $27.34
- 52 Week High
- MASI $194.88
- LEGN $52.15
- Technical
- Relative Strength Index (RSI)
- MASI 41.36
- LEGN 44.99
- Support Level
- MASI $140.11
- LEGN $32.70
- Resistance Level
- MASI $148.95
- LEGN $34.71
- Average True Range (ATR)
- MASI 3.92
- LEGN 1.24
- MACD
- MASI 0.24
- LEGN 0.11
- Stochastic Oscillator
- MASI 41.41
- LEGN 47.16
About MASI Masimo Corporation
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.